Based on the tumor promoting effect of GPNMB and its localization on the surface of tumor cells, targeting GPNMB and its mRNA as therapeutic intervention may inhibit the pulmonary cystic damage and tumor growth of LAM, and slow the progression of the disease. Here, TSC2 is linked to neoplasm.